Comparative Pharmacology
Head-to-head clinical analysis: ABSORICA LD versus ACCUTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSORICA LD versus ACCUTANE.
ABSORICA LD vs ACCUTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and inhibits Propionibacterium acnes growth via modulation of gene expression.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
0.5-1 mg/kg/day orally divided twice daily for 4-5 months, max 2 mg/kg/day.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
None Documented
None Documented
Terminal elimination half-life is 21 hours (range 7–39 hours) for isotretinoin. Clinical context: Steady-state achieved after 5–7 days of dosing.
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Primarily renal, 65% as unchanged drug; 35% as metabolites. Fecal elimination accounts for less than 5%.
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Category C
Category C
Retinoid
Retinoid